RNA

Pfizer is interested in partnering for the advancement of RNA therapeutics and the development of the next generation of RNA medicines

Novel target concepts and therapeutic strategies amenable to RNA based approaches (mRNA, circular RNA, gene editing), in the following areas of interest:

• Cellular reprogramming:
  • Cellular reprogramming in cancer (CRC, Lung, Breast, Prostate, Renal), metabolic, autoimmune disease or fibrosis (e.g. transcription factors). Prioritized lineages include:
    • Myeloid cells (DC, macrophages, monocytes)
    • T cells (induction of Tregs); CAR-Tregs or Treg reprogramming; T cell exhaustion; tolerance
    • Adipocytes, muscle cells, endothelial cells
  • Tunable cytokine/interleukin expression for immune cell modulation in cancer
  • Reprogramming of Myofibroblasts in liver and lung fibrosis
• Infectious Disease Vaccines
  • Protective cell mediated response to bacterial or viral infections
  • Emerging virus threats
  • Bacterial pathogens
• Chronic or Rare Kidney Disease (Focal Segmental Glomerulosclerosis, IgA Nephropathy, Alport Syndrome, or Autosomal Dominant Polycystic Kidney Disease)
• Rare Liver Diseases and Rare Neuromuscular Diseases
• Repeat Expansion Diseases (e.g. Huntington’s disease, Friedreich’s ataxia, ALS, myotonic dystrophy)
• Preference given to targets not amenable to small or large molecule intervention

Technologies and Enabling Infrastructure:

• Gene correction/replacement
• Epigenetic editing
• Delivery technology, including tissue targeting for liver, lung, kidney, immune cell subsets, central nervous system, muscle
• Non-viral delivery for RNA and gene editing
• RNA engineering technologies (e.g. UTRs, IRES, circular RNA, chemical modifications, stability)
• Regulatable gene expression
• Next-gen gene editing

Not actively seeking partnership opportunities in:

• RNA vaccine strategies for Flu, COVID-19, RSV
• Non-coding RNA targets and modalities